Our
Pioneering Approach
We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. We apply our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
Learn more
Our
ProTide Technology
We harness the power of phosphoramidate chemistry to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms and other limitations of existing nucleoside analogs.
Discover MoreOur
Mission Statement
“To significantly improve the survival outcomes for patients by transforming chemotherapy and pioneering a new era in oncology”.
Hugh S. Griffith - Founder & CEO
Learn more
To Transform Chemotherapy and Pioneer a New Era in Oncology
NuCana
Biology for the Future
NuCana features on a news and current affairs style series by ITN Productions and the Royal Society of Biology (RSB).
Our
Leadership Team
Our highly experienced team has a successful track record of building global biopharmaceutical companies and developing new life-saving medicines for patients.
Read MoreOur
Product Pipeline
Our pipeline of new anti-cancer agents have the potential to change the standards of care for patients across a broad range of cancers.
Read More
Our
Latest News
Edinburgh: March 2023
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
More NewsOur
Upcoming Events
Edinburgh: March 2023
American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
MCCormick Place, Chicago, IL
June 2-6, 2023
Our
Contact Details
Global Headquarters
3 Lochside Way, Edinburgh, EH12 9DT, UK
US Office
275 Grove Street, Newton, MA 02466